• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/13/25 4:17:42 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    Alumis Inc._November 13, 2025
    0001847367false00018473672025-11-132025-11-13

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 13, 2025

    Alumis Inc.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

        

    001-42143

        

    86-1771129

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    280 East Grand Avenue

    South San Francisco, California 94080

    (Address of principal executive offices)

    Registrant’s telephone number, including area code: (650) 231-6625

    N/A

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading
    Symbol(s)

        

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share

     

    ALMS

     

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    ​

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    On November 13, 2025, Alumis Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

    All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d)Exhibits.

    ​

    Exhibit No.

        

    Description

    99.1

    Press Release, dated November 13, 2025.

    104

      

    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    Alumis Inc.

    ​

    ​

    ​

    By:

    /s/ Martin Babler

    ​

    ​

    Martin Babler

    ​

    ​

    President and Chief Executive Officer

    ​

    Dated: November 13, 2025

    ​

    Get the next $ALMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    7/25/2025$17.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    More analyst ratings

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,833,760 worth of shares (186,377 units at $9.84) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    12/9/25 7:13:55 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Akkaraju Srinivas bought $2,039,901 worth of shares (262,027 units at $7.79) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    12/4/25 8:11:35 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Capital Management Vi Llc bought $532,925 worth of shares (72,212 units at $7.38) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    11/25/25 4:02:49 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $345.1 million. All of the shares in the offering were sold by Alumis

    1/9/26 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Pricing of Upsized Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300.0 million. All shares in the offering are being sold by Alumis. The offering is expected to close on January 9, 2026, subject to the satisfaction of cus

    1/7/26 10:52:42 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock at the public offering price per share. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the p

    1/6/26 4:12:10 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Alumis with a new price target

    Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00

    7/25/25 9:06:03 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim resumed coverage on Alumis with a new price target

    Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

    6/10/25 8:07:01 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Alumis with a new price target

    Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

    1/30/25 7:47:22 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,833,760 worth of shares (186,377 units at $9.84) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    12/9/25 7:13:55 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Akkaraju Srinivas bought $2,039,901 worth of shares (262,027 units at $7.79) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    12/4/25 8:11:35 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Alumis Inc.

    4 - ALUMIS INC. (0001847367) (Issuer)

    12/1/25 6:09:31 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    SEC Filings

    View All

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ALUMIS INC. (0001847367) (Filer)

    1/9/26 6:02:18 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Alumis Inc.

    424B5 - ALUMIS INC. (0001847367) (Filer)

    1/8/26 5:29:18 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Alumis Inc.

    424B5 - ALUMIS INC. (0001847367) (Filer)

    1/6/26 5:24:26 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    8/27/24 4:20:38 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alumis Inc.

    SC 13G - ALUMIS INC. (0001847367) (Subject)

    7/11/24 4:30:21 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    7/5/24 9:30:17 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Financials

    Live finance-specific insights

    View All

    Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

    – Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

    1/6/26 7:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

    – Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Conference Call and Webcast DetailsAlumis' conference call and webcast to

    1/5/26 5:00:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care